U.S. Life Sciences Stock News

Somnigroup International (SGI) came under pressure after its fourth quarter results and a new dividend declaration, as revenue missed analyst expectations even though sales and earnings for the period were higher than a year earlier. See our latest analysis for Somnigroup International. The fourth quarter earnings and dividend announcement came after a period where the share price has cooled slightly, with a 1-day share price return showing a 1.76% decline and a 90-day share price return...

Xylem (NYSE:XYL) has authorized a new share repurchase program of up to $1.5b. The program allows the company to buy back shares opportunistically over time. The announcement comes with Xylem shares recently trading around $129.56. Xylem, trading on the NYSE under the ticker XYL, is moving ahead with a sizeable $1.5b buyback plan at a share price of about $129.56. Over the past 3 years, the stock has returned 29.3%, and 37.1% over 5 years, which gives context for how management is choosing...

Hagerty (HGTY) closed FY 2025 with Q4 revenue of US$357.3 million and basic EPS of US$0.07, alongside Q4 net income of US$6.9 million. On a trailing twelve month basis, revenue was US$1.5 billion, EPS was US$0.44 and net income was US$41.5 million. Over the last few quarters the company has seen revenue move from US$291.7 million and EPS of US$0.01 in Q4 FY 2024 to US$379.9 million and EPS of US$0.18 in Q3 FY 2025, before landing at the latest Q4 figures. This sets up a story where higher...

Why Houlihan Lokey (HLI) is on investors’ radar today Houlihan Lokey (HLI) has drawn fresh attention after recent share price pressure, with the stock showing a 3.2% decline over the past day and a 9.3% pullback over the past month. See our latest analysis for Houlihan Lokey. That recent 9.3% 1 month share price decline and 7.1% year to date share price pullback sit against a much stronger long run picture, with 3 year total shareholder return of 79.1% and 5 year total shareholder return of...

Willdan Group (WLDN) capped FY 2025 with fourth quarter revenue of US$173.7 million and basic EPS of US$1.28, while trailing twelve month revenue reached US$681.6 million with EPS of US$3.63 as earnings over the last year were reported to have grown 131.8%. Over the past six quarters the company has seen quarterly revenue range from US$144.1 million to US$182.0 million, with basic EPS between US$0.33 and US$1.28. This sets up a story where improving net profit margin to 7.7% from 4% and high...

Vertex, Inc. recently reported past Q4 2025 results showing 9.1% year-over-year revenue growth, outlined 2026 guidance calling for US$823.5–US$831.5 million in revenue with 25% cloud growth, and announced a US$150 million share buyback alongside ongoing AI-enabled tax compliance expansion. Investor attention is also being drawn to a director’s recent open-market share purchase and management’s outlook for continued double-digit revenue growth and improving profit margins, which together...

Shift4 Payments (FOUR) has wrapped up FY 2025 with Q4 revenue of US$1.2b and basic EPS of US$0.37, alongside net income of US$25m that keeps the spotlight firmly on how efficiently each transaction is translating into profit. The company has seen quarterly revenue move from US$909.2m in Q3 2024 to US$848.3m in Q1 2025 and then up to US$1.2b in Q4 2025, while basic EPS shifted from US$0.78 in Q3 2024 to US$0.24 in Q1 2025 and US$0.37 in the latest quarter, setting the stage for investors to...

Starz Entertainment (STRZ) opened Q3 2026 with revenue of US$322.8 million and a basic EPS loss of US$1.24, with trailing twelve month EPS at a loss of US$16.16 on revenue of US$1.3 billion. Over recent quarters, the company has seen quarterly revenue move from US$346.9 million in Q2 2025 to US$344.5 million in Q3 2025, US$330.6 million in Q4 2025, and then settle around US$320.3 million to US$322.8 million across the first three quarters of 2026, while basic EPS losses shifted between...

Xenon Pharmaceuticals (XENE) has put fresh numbers on the table for FY 2025, with first half revenue at US$7.5 million and a basic EPS loss of US$1.90, alongside a trailing twelve month EPS loss of US$4.36. The company has seen revenue move from US$0 in both halves of 2024 to US$7.5 million in the latest half. Basic EPS losses widened from US$1.36 and US$1.64 in the first and second halves of 2024 to US$1.90 most recently and a trailing twelve month net loss of US$345.91 million, keeping...

If you are wondering whether Redwire's share price still reflects its underlying worth, this article will walk through what the current numbers might be telling you about value and risk. The stock last closed at US$9.07, with recent returns ranging from a 13.5% gain over 7 days to a 31.8% decline over 30 days, and a 35.1% decline over the past year, while the 3 year return sits at a very large gain. Recent news around Redwire has focused on its role in the space and defense sectors,...

Gogo (GOGO) closed out FY 2025 with Q4 revenue of US$230.6 million and a basic EPS loss of US$0.07, as investors weighed the latest headline numbers against a still modest trailing profit base. The company has seen quarterly revenue range from US$223.6 million to US$230.6 million across 2025, while basic EPS moved from a profit of US$0.09 in Q1 and US$0.10 in Q2 to small losses of US$0.01 in Q3 and US$0.07 in Q4, creating a mixed picture on earnings momentum and margins. See our full analysis...

Organogenesis Holdings (ORGO) has capped FY 2025 with fourth quarter revenue of US$225.6 million and basic EPS of US$0.28, with trailing twelve month revenue at US$564.2 million and basic EPS of US$0.16. Over recent periods the company has seen quarterly revenue move from US$126.7 million in Q4 2024 to US$225.6 million in Q4 2025, while quarterly EPS shifted from US$0.05 to US$0.28 over the same span, as trailing twelve month EPS moved from roughly breakeven at US$0.01 to US$0.16. For...

American Healthcare REIT (AHR) has wrapped up FY 2025 with Q4 revenue of US$604.1 million and basic EPS of US$0.06, rounding out a trailing twelve month picture that shows total revenue of about US$2.3 billion and basic EPS of US$0.42. Over the past few quarters the REIT has seen revenue move from US$540.2 million in Q4 2024 to US$604.1 million in Q4 2025, while quarterly EPS shifted from a loss of US$0.20 per share to a profit of US$0.06 per share. This sets up a year where investors will be...

GoodRx Holdings (GDRX) is back in focus after launching its Employer Direct platform to help companies reduce high-impact brand drug costs, alongside 2025 earnings, fresh 2026 guidance, and a cluster of analyst rating changes. See our latest analysis for GoodRx Holdings. GoodRx’s recent earnings update, 2026 revenue guidance and the Employer Direct launch have been followed by a sharp reset in sentiment, with a 7 day share price return of 24.29% decline and a 1 year total shareholder return...

Burford Capital (NYSE:BUR) rounded out FY 2025 with Q4 revenue of US$33.4 million and a basic EPS loss of US$0.17, as quarterly earnings swung back into the red despite a profitable first half. The company has seen quarterly revenue move from US$244.9 million and EPS of US$0.62 in Q3 2024 to US$178.0 million and EPS of US$0.40 in Q2 2025, and then to US$64.7 million with an EPS loss of US$0.09 in Q3 2025 before landing at the latest Q4 figures. This sets up a results season in which investors...

Tutor Perini’s FY 2025 Earnings Snapshot Tutor Perini (TPC) has wrapped up FY 2025 with fourth quarter revenue of US$1.5 billion and basic EPS of US$0.55, alongside trailing twelve month revenue of US$5.5 billion and EPS of US$1.53 that mark a clear shift from prior losses. The company has seen quarterly revenue move from US$1.1 billion and an EPS loss of US$1.51 in Q4 2024 to US$1.5 billion and EPS of US$0.55 in Q4 2025. Net income moved from a loss of US$79.4 million to a profit of US$28.8...

SBA Communications (SBAC) closed out FY 2025 with Q4 revenue of US$719.6 million and basic EPS of US$3.48, while trailing twelve month revenue came in at about US$2.8 billion with EPS of US$9.83. Over that same trailing period, net income excluding extra items moved from US$749.5 million to US$1.05 billion, and EPS tracked from US$6.96 to US$9.83, providing a view of how the top and bottom lines have been scaling together. For investors, the combination of higher net margin and a steady...

If you are wondering whether CoStar Group's share price still matches its long term potential, it helps to step back and look closely at what the current market price might be implying about the business. After a last close of US$44.63, the stock has seen sizeable declines, with returns of 10.5% over 7 days, 31.5% over 30 days, 32.1% year to date and 41.5% over 1 year, while the 3 and 5 year returns sit at 38.4% and 44.1% respectively. Recent headlines around CoStar Group have focused on its...

Arcellx (ACLX) closed FY 2025 with fourth quarter revenue of US$1.7 million and a basic EPS loss of US$1.00, alongside a quarterly net loss of US$58.1 million. On a trailing 12 month basis, revenue was US$22.3 million with a basic EPS loss of US$4.07 and a net loss of US$228.9 million. Over the past several quarters, the company has reported quarterly revenue ranging from US$26.0 million in Q3 2024 to US$1.7 million in Q4 2025, with basic EPS losses moving between US$0.48 and US$1.13 over the...

If you are wondering whether Thermon Group Holdings is still attractively priced or already reflecting most of its potential, you are in the right place for a valuation-focused look at the stock. The share price, last closing at US$50.78, comes with a mixed return profile, with a 0.5% decline over 7 days, a 16.9% gain over 30 days, 34.9% year to date, 72.1% over 1 year, 84.6% over 3 years and 136.7% over 5 years. Recent price action sits alongside ongoing news flow around Thermon Group...

On February 13, 2026, Gold.com, Inc. entered into a first amendment to its amended and restated credit agreement, lifting its revolving credit commitments to US$427.5 million and raising limits on secured leases, ownership-based financing, and inventory-related exposures. This expanded borrowing capacity and higher financing thresholds give Gold.com more room to fund operations, inventory, and potential growth initiatives without renegotiating core lending terms. We’ll now examine how...

Qorvo (QRVO) shares were in focus after the company reported fiscal third quarter 2026 results, with adjusted earnings and revenue above estimates, supported by flagship smartphone content, Wi-Fi and automotive ultra-wideband, and defense and aerospace demand. See our latest analysis for Qorvo. Qorvo's latest results and outlook have come against a mixed backdrop for investors, with the 1 month share price return of 7.41% contrasting with a year to date share price decline of 3.91%. The 1...

AvePoint (AVPT) has just wrapped up FY 2025 with Q4 revenue of US$114.7 million and basic EPS of US$0.07, alongside net income of US$15.6 million. The company has seen quarterly revenue move from US$88.8 million in Q3 2024 to US$114.7 million in Q4 2025, while basic EPS shifted from a loss of US$0.09 in Q4 2024 to US$0.07 in Q4 2025, setting up a cleaner profitability profile across the trailing twelve months. Over that period, revenue reached US$419.5 million and basic EPS was US$0.17. With...

Fulgent Genetics (FLGT) just posted its FY 2025 numbers, with fourth quarter revenue of US$83.3 million and a basic EPS loss of US$0.76, alongside net income excluding extra items at a loss of US$23.4 million. The company has seen quarterly revenue move from US$76.2 million in Q4 2024 to US$83.3 million in Q4 2025, while basic EPS shifted from a loss of US$0.19 to a loss of US$0.76 over the same stretch. This sets up a results season where the key question is how much of that top line is...